Please assess the completion status of the following clinical trial:

Trial Title: Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of acute myeloid leukemia (AML) or blastic phase chronic myelogenous leukemia (CML)~  * Refractory AML defined as any of the following:~    * Failure to achieve complete response (CR) after 2 courses of induction chemotherapy~   * Persistent bone marrow blasts \> 40% after 1 course of induction chemotherapy~   * Relapse of disease within 3 months since CR~ * Relapsed AML defined as the following:~    * Any evidence of disease recurrence after CR (early relapse occurs within 3-12 months and late relapse occurs \> 12 months later)~ * No acute promyelocytic leukemia (AML-M3 FAB subgroup)~PATIENT CHARACTERISTICS:~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin ≤ 2.0 mg/dL~* AST ≤ 2.5 times upper limit of normal~* No known chronic liver disease (e.g., chronic active hepatitis or cirrhosis)~Renal~* Creatinine \< 2.5 mg/dL (if 2.0-2.5 mg/dL, glomerular filtration rate must be measured and dose of cytarabine adjusted if necessary)~Cardiovascular~* No New York Heart Association grade III-IV heart disease~* No congestive heart failure~* No myocardial infarction within the past 6 months~* Ejection fraction ≥ 30%~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment~* No uncontrolled systemic active infection~* No known HIV infection~* No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs~* No history of other curatively treated malignancy except nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No other concurrent biologic agents~Chemotherapy~* See Disease Characteristics~* No other concurrent chemotherapy~Endocrine therapy~* No concurrent birth control pills~Other~* More than 1 week since any prior investigational agent~* No other concurrent investigational agents or therapies~* No other concurrent anticancer agents~* No concurrent therapeutic anticoagulation with warfarin~  * Low molecular weight heparin or heparin allowed for therapeutic anticoagulation~ * Mini-dose warfarin (e.g., 1 mg per day) allowed for prophylaxis of central venous catheter thrombosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).